Calendar

««Mar 2010»»
SMTWTFS
  123456
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 3,596,824
since: 14 May 2006

Abstract: Preclinical pharmacology of F-98214-TA, a novel potent SSNRI

posted Saturday, 23 July 2005
Psychopharmacology (Berl). 2005 Jul 20;:1-14 [Epub ahead of print]

Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.

Artaiz I, Zazpe A, Innerarity A, Del Olmo E, Diaz A, Ruiz-Ortega JA, Castro E, Pena R, Labeaga L, Pazos A, Orjales A.

Department of Research, FAES FARMA, S. A., Maximo Aguirre 14, Leioa, 48940, Vizcaya, Spain, aorjales@faes.es.

RATIONALE: Serotonin (5-HT) and norepinephrine (NE) re-uptake inhibitors (SNRIs) have been proposed to have a higher efficacy and/or faster onset of action than previously available antidepressants.

OBJECTIVES: We examined in biochemical, electrophysiological and behavioural assays the antidepressant properties of (S)-(-)-4-[(3-fluorophenoxy)-phenyl]methyl-piperidine (F-98214-TA), a compound that displays very high affinity for 5-HT and NE transporters.

RESULTS: F-98214-TA potently inhibited the uptake of both 5-HT and NE into rat brain synaptosomes (IC(50)=1.9 and 11.2 nM, respectively) and decreased the electrical activity of dorsal raphe serotonergic neurones (ED(50)=530.3 mug/kg i.v.), an effect completely abolished by the 5-HT(1A) antagonist WAY100,635. In acute behavioural assays in mice, the orally administered compound potentiated the 5-hydroxy-tryptophan (5-HTP)-induced syndrome [minimal effective dose (MED)=10 mg/kg], antagonized the hypothermia induced by a high dose of apomorphine (ED(50)=2 mg/kg) and reduced the immobility in the tail suspension test (MED=10 mg/kg). Moreover, it also decreased the immobility in the forced swimming test in mice and rats (30 mg/kg, p.o.). Chronic administration of F-98214-TA (14 days, 30 mg kg(-1) day(-1), p.o.) attenuated the hyperactivity induced by olfactory bulbectomy in rats, confirming its antidepressant-like properties. Interestingly, the same dosage regimen significantly increased the social interaction time in rats, suggesting an additional potential anxiolytic activity. In most assays the compound was more potent than fluoxetine, venlafaxine and desipramine.

CONCLUSIONS: F-98214-TA is a novel SNRI that displays greater potency than other reference antidepressants in animal models predictive of antidepressant and anxiolytic activities.

PMID: 16032410 [PubMed - as supplied by publisher]


(Text has been reformatted for clarity; Ed.)


Source...

links: digg this    del.icio.us    technorati    reddit